Amgen Inc. has been making headlines in the investment and biotech sector.
Thompson Investment Management, Commerzbank Aktiengesellschaft FI, and Aberdeen Group plc have reportedly reduced their positions, selling a significant number of shares.
Drucker Wealth 3.0 LLC, Lmcg Investments LLC, and Sitrin Capital Management LLC have followed suit. Yet, Amgen's perceived undervaluation of
49% has been noted, considering their
strong therapies pipeline, hinting at potentially significant opportunity.
Amgen also announced a
$650M expansion of their facility in
Puerto Rico, which could be a game-changer for its valuation. On the downside, the company’s stock sunk on market gains and Bank of America maintained a ‘sell’ rating, yet they reported outstanding
Q2 earnings and revenue. Further, the price of Amgen's
cholesterol drug Repatha was cut by 60%, in line with Trump’s insistence on reducing drug prices, and launched
AmgenNow with affordable pricing. With a strong momentum and impressive investor attention on this stock, Amgen is considered to be a promising long-term investment in the biotech industry.
Amgen AMGN News Analytics from Mon, 14 Jul 2025 07:00:00 GMT to Sat, 11 Oct 2025 11:43:24 GMT -
Rating 4
- Innovation 7
- Information 6
- Rumor -3
